#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Clinically relevant photodynamic therapy ( PDT ) was introduced about 45 years ago as a novel means for selectively eradicating a variety of solid tumors via cytotoxic photochemistry .
2-1	16-26	Clinically	abstract[2]	new[2]	appos	2-6[0_2]
2-2	27-35	relevant	abstract[2]	new[2]	_	_
2-3	36-48	photodynamic	abstract[2]	new[2]	_	_
2-4	49-56	therapy	abstract[2]	new[2]	_	_
2-5	57-58	(	_	_	_	_
2-6	59-62	PDT	abstract	giv	coref	3-6
2-7	63-64	)	_	_	_	_
2-8	65-68	was	_	_	_	_
2-9	69-79	introduced	_	_	_	_
2-10	80-85	about	time[4]	new[4]	_	_
2-11	86-88	45	time[4]	new[4]	_	_
2-12	89-94	years	time[4]	new[4]	_	_
2-13	95-98	ago	time[4]	new[4]	_	_
2-14	99-101	as	_	_	_	_
2-15	102-103	a	abstract[5]	new[5]	_	_
2-16	104-109	novel	abstract[5]	new[5]	_	_
2-17	110-115	means	abstract[5]	new[5]	_	_
2-18	116-119	for	abstract[5]	new[5]	_	_
2-19	120-131	selectively	abstract[5]	new[5]	_	_
2-20	132-143	eradicating	abstract[5]	new[5]	_	_
2-21	144-145	a	abstract[5]|abstract[6]	new[5]|new[6]	_	_
2-22	146-153	variety	abstract[5]|abstract[6]	new[5]|new[6]	_	_
2-23	154-156	of	abstract[5]|abstract[6]	new[5]|new[6]	_	_
2-24	157-162	solid	abstract[5]|abstract[6]|object[7]	new[5]|new[6]|new[7]	coref	7-16[48_7]
2-25	163-169	tumors	abstract[5]|abstract[6]|object[7]	new[5]|new[6]|new[7]	_	_
2-26	170-173	via	abstract[5]	new[5]	_	_
2-27	174-183	cytotoxic	abstract[5]|abstract[8]	new[5]|new[8]	_	_
2-28	184-198	photochemistry	abstract[5]|abstract[8]	new[5]|new[8]	_	_
2-29	199-200	.	_	_	_	_

#Text=As an anti-tumor modality , PDT is unique in requiring three components : a photosensitizing agent ( PS ) , PS-exciting light in the far-visible-to-near-infrared range , and molecular oxygen .
3-1	201-203	As	_	_	_	_
3-2	204-206	an	abstract[9]	new[9]	_	_
3-3	207-217	anti-tumor	abstract[9]	new[9]	_	_
3-4	218-226	modality	abstract[9]	new[9]	_	_
3-5	227-228	,	_	_	_	_
3-6	229-232	PDT	abstract	giv	coref	4-4
3-7	233-235	is	_	_	_	_
3-8	236-242	unique	_	_	_	_
3-9	243-245	in	_	_	_	_
3-10	246-255	requiring	_	_	_	_
3-11	256-261	three	substance[11]	new[11]	appos	3-21[15_11]
3-12	262-272	components	substance[11]	new[11]	_	_
3-13	273-274	:	_	_	_	_
3-14	275-276	a	substance[12]	new[12]	_	_
3-15	277-293	photosensitizing	substance[12]	new[12]	_	_
3-16	294-299	agent	substance[12]	new[12]	_	_
3-17	300-301	(	_	_	_	_
3-18	302-304	PS	abstract	new	_	_
3-19	305-306	)	_	_	_	_
3-20	307-308	,	_	_	_	_
3-21	309-320	PS-exciting	event|substance[15]	new|giv[15]	appos	3-29[17_15]
3-22	321-326	light	substance[15]	giv[15]	_	_
3-23	327-329	in	substance[15]	giv[15]	_	_
3-24	330-333	the	substance[15]|abstract[16]	giv[15]|new[16]	_	_
3-25	334-362	far-visible-to-near-infrared	substance[15]|abstract[16]	giv[15]|new[16]	_	_
3-26	363-368	range	substance[15]|abstract[16]	giv[15]|new[16]	_	_
3-27	369-370	,	_	_	_	_
3-28	371-374	and	_	_	_	_
3-29	375-384	molecular	substance[17]	giv[17]	_	_
3-30	385-391	oxygen	substance[17]	giv[17]	_	_
3-31	392-393	.	_	_	_	_

#Text=PS photoexcitation during PDT gives rise to cytotoxic reactive oxygen species ( ROS ) such as singlet oxygen ( 1O2 ) .
4-1	394-396	PS	abstract[18]	new[18]	_	_
4-2	397-412	photoexcitation	abstract[18]	new[18]	_	_
4-3	413-419	during	abstract[18]	new[18]	_	_
4-4	420-423	PDT	abstract[18]|abstract	new[18]|giv	coref	5-9
4-5	424-429	gives	_	_	_	_
4-6	430-434	rise	event	new	_	_
4-7	435-437	to	_	_	_	_
4-8	438-447	cytotoxic	abstract[22]	new[22]	appos	4-13[0_22]
4-9	448-456	reactive	substance[21]|abstract[22]	new[21]|new[22]	_	_
4-10	457-463	oxygen	substance[21]|abstract[22]	new[21]|new[22]	_	_
4-11	464-471	species	abstract[22]	new[22]	_	_
4-12	472-473	(	_	_	_	_
4-13	474-477	ROS	abstract	giv	_	_
4-14	478-479	)	_	_	_	_
4-15	480-484	such	_	_	_	_
4-16	485-487	as	_	_	_	_
4-17	488-495	singlet	substance|substance[25]	new|new[25]	coref	15-27[0_25]
4-18	496-502	oxygen	substance[25]	new[25]	_	_
4-19	503-504	(	_	_	_	_
4-20	505-508	1O2	abstract	new	_	_
4-21	509-510	)	_	_	_	_
4-22	511-512	.	_	_	_	_

#Text=The first PS to receive FDA approval for PDT applications was Photofrin® , an oligomeric form of hematoporphyrin that continues to be used for a variety of malignancies .
5-1	513-516	The	abstract[27]	new[27]	coref	5-12[0_27]
5-2	517-522	first	abstract[27]	new[27]	_	_
5-3	523-525	PS	abstract[27]	new[27]	_	_
5-4	526-528	to	abstract[27]	new[27]	_	_
5-5	529-536	receive	abstract[27]	new[27]	_	_
5-6	537-540	FDA	abstract[27]|abstract[28]	new[27]|new[28]	_	_
5-7	541-549	approval	abstract[27]|abstract[28]	new[27]|new[28]	_	_
5-8	550-553	for	abstract[27]	new[27]	_	_
5-9	554-557	PDT	abstract[27]|abstract|abstract[30]	new[27]|giv|new[30]	coref	6-8
5-10	558-570	applications	abstract[27]|abstract[30]	new[27]|new[30]	_	_
5-11	571-574	was	_	_	_	_
5-12	575-585	Photofrin®	abstract	giv	coref	8-9
5-13	586-587	,	_	_	_	_
5-14	588-590	an	substance[32]	new[32]	_	_
5-15	591-601	oligomeric	substance[32]	new[32]	_	_
5-16	602-606	form	substance[32]	new[32]	_	_
5-17	607-609	of	substance[32]	new[32]	_	_
5-18	610-625	hematoporphyrin	substance[32]|abstract[33]	new[32]|new[33]	_	_
5-19	626-630	that	substance[32]|abstract[33]	new[32]|new[33]	_	_
5-20	631-640	continues	substance[32]|abstract[33]	new[32]|new[33]	_	_
5-21	641-643	to	substance[32]|abstract[33]	new[32]|new[33]	_	_
5-22	644-646	be	substance[32]|abstract[33]	new[32]|new[33]	_	_
5-23	647-651	used	substance[32]|abstract[33]	new[32]|new[33]	_	_
5-24	652-655	for	_	_	_	_
5-25	656-657	a	abstract[34]	new[34]	_	_
5-26	658-665	variety	abstract[34]	new[34]	_	_
5-27	666-668	of	abstract[34]	new[34]	_	_
5-28	669-681	malignancies	abstract[34]|abstract	new[34]|new	_	_
5-29	682-683	.	_	_	_	_

#Text=Unlike more conventional chemotherapy or radiotherapy , PDT has few ( if any ) light-independent side effects and is non-invasive and site-specific , i.e. , limited to the tumor upon which light is directed , typically via fiber optic networks .
6-1	684-690	Unlike	_	_	_	_
6-2	691-695	more	abstract[36]	new[36]	coref	12-13[0_36]
6-3	696-708	conventional	abstract[36]	new[36]	_	_
6-4	709-721	chemotherapy	abstract[36]	new[36]	_	_
6-5	722-724	or	_	_	_	_
6-6	725-737	radiotherapy	abstract	new	coref	12-11
6-7	738-739	,	_	_	_	_
6-8	740-743	PDT	abstract	giv	coref	7-3
6-9	744-747	has	_	_	_	_
6-10	748-751	few	abstract[40]	new[40]	coref	17-4[133_40]
6-11	752-753	(	abstract[40]	new[40]	_	_
6-12	754-756	if	abstract[40]	new[40]	_	_
6-13	757-760	any	abstract[40]	new[40]	_	_
6-14	761-762	)	abstract[40]	new[40]	_	_
6-15	763-780	light-independent	abstract[40]	new[40]	_	_
6-16	781-785	side	abstract|abstract[40]	new|new[40]	_	_
6-17	786-793	effects	abstract[40]	new[40]	_	_
6-18	794-797	and	_	_	_	_
6-19	798-800	is	_	_	_	_
6-20	801-813	non-invasive	_	_	_	_
6-21	814-817	and	_	_	_	_
6-22	818-831	site-specific	_	_	_	_
6-23	832-833	,	_	_	_	_
6-24	834-838	i.e.	_	_	_	_
6-25	839-840	,	_	_	_	_
6-26	841-848	limited	_	_	_	_
6-27	849-851	to	_	_	_	_
6-28	852-855	the	object[41]	new[41]	coref	10-6[0_41]
6-29	856-861	tumor	object[41]	new[41]	_	_
6-30	862-866	upon	object[41]	new[41]	_	_
6-31	867-872	which	object[41]	new[41]	_	_
6-32	873-878	light	object[41]|abstract	new[41]|new	_	_
6-33	879-881	is	object[41]	new[41]	_	_
6-34	882-890	directed	object[41]	new[41]	_	_
6-35	891-892	,	_	_	_	_
6-36	893-902	typically	abstract[44]	new[44]	_	_
6-37	903-906	via	abstract[44]	new[44]	_	_
6-38	907-912	fiber	substance|abstract[44]	new|new[44]	_	_
6-39	913-918	optic	abstract[44]	new[44]	_	_
6-40	919-927	networks	abstract[44]	new[44]	_	_
6-41	928-929	.	_	_	_	_

#Text=Moreover , PDT can often overcome the innate or acquired resistance to other therapies that many tumors exhibit .
7-1	930-938	Moreover	_	_	_	_
7-2	939-940	,	_	_	_	_
7-3	941-944	PDT	abstract	giv	coref	11-7
7-4	945-948	can	_	_	_	_
7-5	949-954	often	_	_	_	_
7-6	955-963	overcome	_	_	_	_
7-7	964-967	the	abstract[46]	new[46]	coref	12-5[85_46]
7-8	968-974	innate	abstract[46]	new[46]	_	_
7-9	975-977	or	abstract[46]	new[46]	_	_
7-10	978-986	acquired	abstract[46]	new[46]	_	_
7-11	987-997	resistance	abstract[46]	new[46]	_	_
7-12	998-1000	to	abstract[46]	new[46]	_	_
7-13	1001-1006	other	abstract[46]|abstract[47]	new[46]|new[47]	_	_
7-14	1007-1016	therapies	abstract[46]|abstract[47]	new[46]|new[47]	_	_
7-15	1017-1021	that	abstract[46]	new[46]	_	_
7-16	1022-1026	many	abstract[46]|object[48]	new[46]|giv[48]	_	_
7-17	1027-1033	tumors	abstract[46]|object[48]	new[46]|giv[48]	_	_
7-18	1034-1041	exhibit	abstract[46]	new[46]	_	_
7-19	1042-1043	.	_	_	_	_

#Text=In addition to pre-existing administered sensitizers such as Photofrin® , pro-sensitizers have been developed , one common example being 5-aminolevulinic acid ( ALA ) .
8-1	1044-1046	In	_	_	_	_
8-2	1047-1055	addition	_	_	_	_
8-3	1056-1058	to	_	_	_	_
8-4	1059-1071	pre-existing	abstract[49]	new[49]	_	_
8-5	1072-1084	administered	abstract[49]	new[49]	_	_
8-6	1085-1096	sensitizers	abstract[49]	new[49]	_	_
8-7	1097-1101	such	abstract[49]	new[49]	_	_
8-8	1102-1104	as	abstract[49]	new[49]	_	_
8-9	1105-1115	Photofrin®	abstract[49]|abstract	new[49]|giv	_	_
8-10	1116-1117	,	_	_	_	_
8-11	1118-1133	pro-sensitizers	object	new	_	_
8-12	1134-1138	have	_	_	_	_
8-13	1139-1143	been	_	_	_	_
8-14	1144-1153	developed	_	_	_	_
8-15	1154-1155	,	_	_	_	_
8-16	1156-1159	one	substance[52]	new[52]	coref	8-20[53_52]
8-17	1160-1166	common	substance[52]	new[52]	_	_
8-18	1167-1174	example	substance[52]	new[52]	_	_
8-19	1175-1180	being	_	_	_	_
8-20	1181-1197	5-aminolevulinic	substance[53]	giv[53]	coref	9-7[57_53]
8-21	1198-1202	acid	substance[53]	giv[53]	_	_
8-22	1203-1204	(	_	_	_	_
8-23	1205-1208	ALA	place	new	coref	9-11
8-24	1209-1210	)	_	_	_	_
8-25	1211-1212	.	_	_	_	_

#Text=Upon entering cancer cells via an amino acid transporter , ALA is metabolized to protoporphyrin IX ( PpIX ) , the active PS , via the heme biosynthetic pathway , PpIX accumulating initially in mitochondria .
9-1	1213-1217	Upon	_	_	_	_
9-2	1218-1226	entering	_	_	_	_
9-3	1227-1233	cancer	abstract|plant[56]	new|new[56]	coref|coref	10-6[69_56]|12-2
9-4	1234-1239	cells	plant[56]	new[56]	_	_
9-5	1240-1243	via	_	_	_	_
9-6	1244-1246	an	abstract[58]	new[58]	_	_
9-7	1247-1252	amino	substance[57]|abstract[58]	giv[57]|new[58]	_	_
9-8	1253-1257	acid	substance[57]|abstract[58]	giv[57]|new[58]	_	_
9-9	1258-1269	transporter	abstract[58]	new[58]	_	_
9-10	1270-1271	,	_	_	_	_
9-11	1272-1275	ALA	place	giv	coref	11-19
9-12	1276-1278	is	_	_	_	_
9-13	1279-1290	metabolized	_	_	_	_
9-14	1291-1293	to	_	_	_	_
9-15	1294-1308	protoporphyrin	abstract[60]	new[60]	appos	9-18[0_60]
9-16	1309-1311	IX	abstract[60]	new[60]	_	_
9-17	1312-1313	(	_	_	_	_
9-18	1314-1318	PpIX	abstract	giv	appos	9-21[62_0]
9-19	1319-1320	)	_	_	_	_
9-20	1321-1322	,	_	_	_	_
9-21	1323-1326	the	abstract[62]	giv[62]	coref	9-31[0_62]
9-22	1327-1333	active	abstract[62]	giv[62]	_	_
9-23	1334-1336	PS	abstract[62]	giv[62]	_	_
9-24	1337-1338	,	_	_	_	_
9-25	1339-1342	via	_	_	_	_
9-26	1343-1346	the	abstract[64]	new[64]	_	_
9-27	1347-1351	heme	substance|abstract[64]	new|new[64]	coref	10-12
9-28	1352-1364	biosynthetic	abstract[64]	new[64]	_	_
9-29	1365-1372	pathway	abstract[64]	new[64]	_	_
9-30	1373-1374	,	_	_	_	_
9-31	1375-1379	PpIX	abstract	giv	coref	11-10[76_0]
9-32	1380-1392	accumulating	_	_	_	_
9-33	1393-1402	initially	_	_	_	_
9-34	1403-1405	in	_	_	_	_
9-35	1406-1418	mitochondria	animal	new	_	_
9-36	1419-1420	.	_	_	_	_

#Text=For rapid proliferative needs , tumor cells are more active in heme synthesis than normal counterparts .
10-1	1421-1424	For	_	_	_	_
10-2	1425-1430	rapid	abstract[67]	new[67]	_	_
10-3	1431-1444	proliferative	abstract[67]	new[67]	_	_
10-4	1445-1450	needs	abstract[67]	new[67]	_	_
10-5	1451-1452	,	_	_	_	_
10-6	1453-1458	tumor	object|plant[69]	giv|giv[69]	coref|coref	11-35|12-1[84_69]
10-7	1459-1464	cells	plant[69]	giv[69]	_	_
10-8	1465-1468	are	_	_	_	_
10-9	1469-1473	more	_	_	_	_
10-10	1474-1480	active	_	_	_	_
10-11	1481-1483	in	_	_	_	_
10-12	1484-1488	heme	substance|abstract[71]	giv|new[71]	_	_
10-13	1489-1498	synthesis	abstract[71]	new[71]	_	_
10-14	1499-1503	than	_	_	_	_
10-15	1504-1510	normal	animal[72]	new[72]	_	_
10-16	1511-1523	counterparts	animal[72]	new[72]	_	_
10-17	1524-1525	.	_	_	_	_

#Text=In addition to acting as a PDT sensitizer , ALA-induced PpIX , like that induced by more lipophilic ALA esters , e.g. , Hexvix , can serve as a highly effective fluorophore for image-guided tumor resection .
11-1	1526-1528	In	_	_	_	_
11-2	1529-1537	addition	_	_	_	_
11-3	1538-1540	to	_	_	_	_
11-4	1541-1547	acting	_	_	_	_
11-5	1548-1550	as	_	_	_	_
11-6	1551-1552	a	abstract[74]	new[74]	_	_
11-7	1553-1556	PDT	abstract|abstract[74]	giv|new[74]	coref	12-18
11-8	1557-1567	sensitizer	abstract[74]	new[74]	_	_
11-9	1568-1569	,	_	_	_	_
11-10	1570-1581	ALA-induced	abstract|abstract[76]	new|giv[76]	coref	13-11[94_76]
11-11	1582-1586	PpIX	abstract[76]	giv[76]	_	_
11-12	1587-1588	,	abstract[76]	giv[76]	_	_
11-13	1589-1593	like	abstract[76]	giv[76]	_	_
11-14	1594-1598	that	abstract[76]	giv[76]	_	_
11-15	1599-1606	induced	abstract[76]	giv[76]	_	_
11-16	1607-1609	by	abstract[76]	giv[76]	_	_
11-17	1610-1614	more	abstract[76]|substance[78]	giv[76]|new[78]	_	_
11-18	1615-1625	lipophilic	abstract[76]|substance[78]	giv[76]|new[78]	_	_
11-19	1626-1629	ALA	abstract[76]|place|substance[78]	giv[76]|giv|new[78]	_	_
11-20	1630-1636	esters	abstract[76]|substance[78]	giv[76]|new[78]	_	_
11-21	1637-1638	,	_	_	_	_
11-22	1639-1643	e.g.	animal[79]	new[79]	_	_
11-23	1644-1645	,	animal[79]	new[79]	_	_
11-24	1646-1652	Hexvix	animal[79]	new[79]	_	_
11-25	1653-1654	,	_	_	_	_
11-26	1655-1658	can	_	_	_	_
11-27	1659-1664	serve	_	_	_	_
11-28	1665-1667	as	_	_	_	_
11-29	1668-1669	a	substance[80]	new[80]	_	_
11-30	1670-1676	highly	substance[80]	new[80]	_	_
11-31	1677-1686	effective	substance[80]	new[80]	_	_
11-32	1687-1698	fluorophore	substance[80]	new[80]	_	_
11-33	1699-1702	for	substance[80]	new[80]	_	_
11-34	1703-1715	image-guided	substance[80]|event[82]	new[80]|new[82]	_	_
11-35	1716-1721	tumor	substance[80]|object|event[82]	new[80]|giv|new[82]	coref	22-2[169_0]
11-36	1722-1731	resection	substance[80]|event[82]	new[80]|new[82]	_	_
11-37	1732-1733	.	_	_	_	_

#Text=Many cancer cells exhibit an intrinsic or acquired resistance to radiotherapy or chemotherapy , and resistance to PDT has also been demonstrated .
12-1	1734-1738	Many	plant[84]	giv[84]	coref	15-39[0_84]
12-2	1739-1745	cancer	abstract|plant[84]	giv|giv[84]	coref	16-37
12-3	1746-1751	cells	plant[84]	giv[84]	_	_
12-4	1752-1759	exhibit	_	_	_	_
12-5	1760-1762	an	abstract[85]	giv[85]	coref	12-16[88_85]
12-6	1763-1772	intrinsic	abstract[85]	giv[85]	_	_
12-7	1773-1775	or	abstract[85]	giv[85]	_	_
12-8	1776-1784	acquired	abstract[85]	giv[85]	_	_
12-9	1785-1795	resistance	abstract[85]	giv[85]	_	_
12-10	1796-1798	to	abstract[85]	giv[85]	_	_
12-11	1799-1811	radiotherapy	abstract[85]|abstract	giv[85]|giv	_	_
12-12	1812-1814	or	abstract[85]	giv[85]	_	_
12-13	1815-1827	chemotherapy	abstract[85]|abstract	giv[85]|giv	_	_
12-14	1828-1829	,	_	_	_	_
12-15	1830-1833	and	_	_	_	_
12-16	1834-1844	resistance	abstract[88]	giv[88]	coref	13-6[0_88]
12-17	1845-1847	to	abstract[88]	giv[88]	_	_
12-18	1848-1851	PDT	abstract[88]|abstract	giv[88]|giv	coref	23-23
12-19	1852-1855	has	_	_	_	_
12-20	1856-1860	also	_	_	_	_
12-21	1861-1865	been	_	_	_	_
12-22	1866-1878	demonstrated	_	_	_	_
12-23	1879-1880	.	_	_	_	_

#Text=For ALA-PDT , one notable resistance mechanism involves efflux of newly synthesized PpIX via the plasma membrane transporter ABCG2 .
13-1	1881-1884	For	_	_	_	_
13-2	1885-1892	ALA-PDT	abstract	new	_	_
13-3	1893-1894	,	_	_	_	_
13-4	1895-1898	one	abstract[92]	new[92]	coref	14-1[99_92]
13-5	1899-1906	notable	abstract[92]	new[92]	_	_
13-6	1907-1917	resistance	abstract|abstract[92]	giv|new[92]	coref	16-32[129_0]
13-7	1918-1927	mechanism	abstract[92]	new[92]	_	_
13-8	1928-1936	involves	_	_	_	_
13-9	1937-1943	efflux	event[93]	new[93]	_	_
13-10	1944-1946	of	event[93]	new[93]	_	_
13-11	1947-1952	newly	event[93]|abstract[94]	new[93]|giv[94]	coref	18-25[148_94]
13-12	1953-1964	synthesized	event[93]|abstract[94]	new[93]|giv[94]	_	_
13-13	1965-1969	PpIX	event[93]|abstract[94]	new[93]|giv[94]	_	_
13-14	1970-1973	via	_	_	_	_
13-15	1974-1977	the	person[97]|abstract[98]	new[97]|new[98]	_	_
13-16	1978-1984	plasma	abstract|substance[96]|person[97]|abstract[98]	new|new[96]|new[97]|new[98]	_	_
13-17	1985-1993	membrane	substance[96]|person[97]|abstract[98]	new[96]|new[97]|new[98]	_	_
13-18	1994-2005	transporter	person[97]|abstract[98]	new[97]|new[98]	_	_
13-19	2006-2011	ABCG2	abstract[98]	new[98]	_	_
13-20	2012-2013	.	_	_	_	_

#Text=Another important mechanism involves nitric oxide ( NO ) generated by constitutive and/or PDT stress-upregulated inducible nitric oxide synthase ( iNOS/NOS2 ) .
14-1	2014-2021	Another	abstract[99]	giv[99]	_	_
14-2	2022-2031	important	abstract[99]	giv[99]	_	_
14-3	2032-2041	mechanism	abstract[99]	giv[99]	_	_
14-4	2042-2050	involves	_	_	_	_
14-5	2051-2057	nitric	abstract|substance[101]	new|new[101]	coref|coref	14-17|14-16[106_101]
14-6	2058-2063	oxide	substance[101]	new[101]	_	_
14-7	2064-2065	(	_	_	_	_
14-8	2066-2068	NO	abstract	new	coref	15-1
14-9	2069-2070	)	_	_	_	_
14-10	2071-2080	generated	_	_	_	_
14-11	2081-2083	by	_	_	_	_
14-12	2084-2096	constitutive	abstract[107]	new[107]	appos	14-21[0_107]
14-13	2097-2103	and/or	abstract[107]	new[107]	_	_
14-14	2104-2107	PDT	abstract[107]	new[107]	_	_
14-15	2108-2126	stress-upregulated	abstract|abstract[107]	new|new[107]	_	_
14-16	2127-2136	inducible	abstract|substance[106]|abstract[107]	new|giv[106]|new[107]	_	_
14-17	2137-2143	nitric	abstract|substance[106]|abstract[107]	giv|giv[106]|new[107]	_	_
14-18	2144-2149	oxide	substance[106]|abstract[107]	giv[106]|new[107]	_	_
14-19	2150-2158	synthase	abstract[107]	new[107]	_	_
14-20	2159-2160	(	_	_	_	_
14-21	2161-2170	iNOS/NOS2	abstract	giv	_	_
14-22	2171-2172	)	_	_	_	_
14-23	2173-2174	.	_	_	_	_

#Text=NO is a bioactive free radical molecule ( 1 – 2 sec lifetime in water ) that diffuses freely on its own and , similar to oxygen ( O2 ) , tends to partition into hydrophobic regions of cells , e.g. , cell membranes .
15-1	2175-2177	NO	abstract	giv	coref	15-3[110_0]
15-2	2178-2180	is	_	_	_	_
15-3	2181-2182	a	abstract[110]	giv[110]	coref	16-17[0_110]
15-4	2183-2192	bioactive	abstract[110]	giv[110]	_	_
15-5	2193-2197	free	abstract[110]	giv[110]	_	_
15-6	2198-2205	radical	abstract[110]	giv[110]	_	_
15-7	2206-2214	molecule	abstract[110]	giv[110]	_	_
15-8	2215-2216	(	_	_	_	_
15-9	2217-2218	1	person[111]|abstract[112]	new[111]|new[112]	_	_
15-10	2219-2220	–	person[111]|abstract[112]	new[111]|new[112]	_	_
15-11	2221-2222	2	person[111]|abstract[112]	new[111]|new[112]	_	_
15-12	2223-2226	sec	person[111]|abstract[112]	new[111]|new[112]	_	_
15-13	2227-2235	lifetime	abstract[112]	new[112]	_	_
15-14	2236-2238	in	abstract[112]	new[112]	_	_
15-15	2239-2244	water	abstract[112]|substance	new[112]|new	ana	15-21
15-16	2245-2246	)	_	_	_	_
15-17	2247-2251	that	_	_	_	_
15-18	2252-2260	diffuses	_	_	_	_
15-19	2261-2267	freely	_	_	_	_
15-20	2268-2270	on	_	_	_	_
15-21	2271-2274	its	substance	giv	_	_
15-22	2275-2278	own	_	_	_	_
15-23	2279-2282	and	_	_	_	_
15-24	2283-2284	,	_	_	_	_
15-25	2285-2292	similar	_	_	_	_
15-26	2293-2295	to	_	_	_	_
15-27	2296-2302	oxygen	substance	giv	_	_
15-28	2303-2304	(	_	_	_	_
15-29	2305-2307	O2	abstract	new	_	_
15-30	2308-2309	)	_	_	_	_
15-31	2310-2311	,	_	_	_	_
15-32	2312-2317	tends	_	_	_	_
15-33	2318-2320	to	_	_	_	_
15-34	2321-2330	partition	_	_	_	_
15-35	2331-2335	into	_	_	_	_
15-36	2336-2347	hydrophobic	place[117]	new[117]	appos	15-41[120_117]
15-37	2348-2355	regions	place[117]	new[117]	_	_
15-38	2356-2358	of	place[117]	new[117]	_	_
15-39	2359-2364	cells	place[117]|plant	new[117]|giv	coref	16-35[131_0]
15-40	2365-2366	,	_	_	_	_
15-41	2367-2371	e.g.	place[120]	giv[120]	_	_
15-42	2372-2373	,	place[120]	giv[120]	_	_
15-43	2374-2378	cell	place|place[120]	new|giv[120]	coref	18-10
15-44	2379-2388	membranes	place[120]	giv[120]	_	_
15-45	2389-2390	.	_	_	_	_

#Text=At relatively low steady state levels ( e.g. , 50 – 300 nM range ) , NO is known to play a key signaling role in survival , migration , and drug resistance of many different cancer cells .
16-1	2391-2393	At	_	_	_	_
16-2	2394-2404	relatively	abstract[122]	new[122]	_	_
16-3	2405-2408	low	abstract[122]	new[122]	_	_
16-4	2409-2415	steady	abstract[121]|abstract[122]	new[121]|new[122]	_	_
16-5	2416-2421	state	abstract[121]|abstract[122]	new[121]|new[122]	_	_
16-6	2422-2428	levels	abstract[122]	new[122]	_	_
16-7	2429-2430	(	_	_	_	_
16-8	2431-2435	e.g.	object[123]	new[123]	_	_
16-9	2436-2437	,	object[123]	new[123]	_	_
16-10	2438-2440	50	object[123]	new[123]	_	_
16-11	2441-2442	–	object[123]	new[123]	_	_
16-12	2443-2446	300	object[123]	new[123]	_	_
16-13	2447-2449	nM	object[123]	new[123]	_	_
16-14	2450-2455	range	_	_	_	_
16-15	2456-2457	)	_	_	_	_
16-16	2458-2459	,	_	_	_	_
16-17	2460-2462	NO	abstract	giv	coref	17-8[134_0]
16-18	2463-2465	is	_	_	_	_
16-19	2466-2471	known	_	_	_	_
16-20	2472-2474	to	_	_	_	_
16-21	2475-2479	play	_	_	_	_
16-22	2480-2481	a	abstract[125]	new[125]	_	_
16-23	2482-2485	key	abstract[125]	new[125]	_	_
16-24	2486-2495	signaling	abstract[125]	new[125]	_	_
16-25	2496-2500	role	abstract[125]	new[125]	_	_
16-26	2501-2503	in	abstract[125]	new[125]	_	_
16-27	2504-2512	survival	abstract[125]|event	new[125]|new	_	_
16-28	2513-2514	,	abstract[125]	new[125]	_	_
16-29	2515-2524	migration	abstract[125]|abstract	new[125]|new	_	_
16-30	2525-2526	,	abstract[125]	new[125]	_	_
16-31	2527-2530	and	abstract[125]	new[125]	_	_
16-32	2531-2535	drug	abstract[125]|substance|abstract[129]	new[125]|new|giv[129]	ana	17-1[0_129]
16-33	2536-2546	resistance	abstract[125]|abstract[129]	new[125]|giv[129]	_	_
16-34	2547-2549	of	abstract[125]|abstract[129]	new[125]|giv[129]	_	_
16-35	2550-2554	many	abstract[125]|abstract[129]|plant[131]	new[125]|giv[129]|giv[131]	coref	19-5[151_131]
16-36	2555-2564	different	abstract[125]|abstract[129]|plant[131]	new[125]|giv[129]|giv[131]	_	_
16-37	2565-2571	cancer	abstract[125]|abstract[129]|abstract|plant[131]	new[125]|giv[129]|giv|giv[131]	coref	18-9
16-38	2572-2577	cells	abstract[125]|abstract[129]|plant[131]	new[125]|giv[129]|giv[131]	_	_
16-39	2578-2579	.	_	_	_	_

#Text=This contrasts with the cytotoxic effects of NO produced at much higher levels ( ≥1 µM ) by activated macrophages during an inflammatory response , e.g. , to infection .
17-1	2580-2584	This	abstract	giv	_	_
17-2	2585-2594	contrasts	_	_	_	_
17-3	2595-2599	with	_	_	_	_
17-4	2600-2603	the	abstract[133]	giv[133]	coref	23-11[183_133]
17-5	2604-2613	cytotoxic	abstract[133]	giv[133]	_	_
17-6	2614-2621	effects	abstract[133]	giv[133]	_	_
17-7	2622-2624	of	abstract[133]	giv[133]	_	_
17-8	2625-2627	NO	abstract[133]|abstract[134]	giv[133]|giv[134]	coref	18-17[0_134]
17-9	2628-2636	produced	abstract[133]|abstract[134]	giv[133]|giv[134]	_	_
17-10	2637-2639	at	abstract[133]|abstract[134]	giv[133]|giv[134]	_	_
17-11	2640-2644	much	abstract[133]|abstract[134]|abstract[135]	giv[133]|giv[134]|new[135]	appos	17-15[136_135]
17-12	2645-2651	higher	abstract[133]|abstract[134]|abstract[135]	giv[133]|giv[134]|new[135]	_	_
17-13	2652-2658	levels	abstract[133]|abstract[134]|abstract[135]	giv[133]|giv[134]|new[135]	_	_
17-14	2659-2660	(	abstract[133]|abstract[134]	giv[133]|giv[134]	_	_
17-15	2661-2663	≥1	abstract[133]|abstract[134]|abstract[136]	giv[133]|giv[134]|giv[136]	_	_
17-16	2664-2666	µM	abstract[133]|abstract[134]|abstract[136]	giv[133]|giv[134]|giv[136]	_	_
17-17	2667-2668	)	abstract[133]|abstract[134]	giv[133]|giv[134]	_	_
17-18	2669-2671	by	abstract[133]|abstract[134]	giv[133]|giv[134]	_	_
17-19	2672-2681	activated	abstract[133]|abstract[134]|animal[137]	giv[133]|giv[134]|new[137]	_	_
17-20	2682-2693	macrophages	abstract[133]|abstract[134]|animal[137]	giv[133]|giv[134]|new[137]	_	_
17-21	2694-2700	during	_	_	_	_
17-22	2701-2703	an	event[138]	new[138]	coref	21-12[166_138]
17-23	2704-2716	inflammatory	event[138]	new[138]	_	_
17-24	2717-2725	response	event[138]	new[138]	_	_
17-25	2726-2727	,	event[138]	new[138]	_	_
17-26	2728-2732	e.g.	event[138]|event[139]	new[138]|new[139]	_	_
17-27	2733-2734	,	event[138]|event[139]	new[138]|new[139]	_	_
17-28	2735-2737	to	event[138]|event[139]	new[138]|new[139]	_	_
17-29	2738-2747	infection	event[138]|event[139]	new[138]|new[139]	_	_
17-30	2748-2749	.	_	_	_	_

#Text=In previous work , we discovered that various cancer cell lines significantly upregulate cytoprotective iNOS and NO after a moderate photodynamic challenge sensitized by ALA-induced PpIX .
18-1	2750-2752	In	_	_	_	_
18-2	2753-2761	previous	abstract[140]	new[140]	_	_
18-3	2762-2766	work	abstract[140]	new[140]	_	_
18-4	2767-2768	,	_	_	_	_
18-5	2769-2771	we	person	acc	ana	21-1
18-6	2772-2782	discovered	_	_	_	_
18-7	2783-2787	that	_	_	_	_
18-8	2788-2795	various	object[144]	new[144]	coref	24-11[191_144]
18-9	2796-2802	cancer	abstract|object[144]	giv|new[144]	coref	23-3[178_0]
18-10	2803-2807	cell	place|object[144]	giv|new[144]	_	_
18-11	2808-2813	lines	object[144]	new[144]	_	_
18-12	2814-2827	significantly	_	_	_	_
18-13	2828-2838	upregulate	_	_	_	_
18-14	2839-2853	cytoprotective	abstract[145]	new[145]	coref	20-27[0_145]
18-15	2854-2858	iNOS	abstract[145]	new[145]	_	_
18-16	2859-2862	and	_	_	_	_
18-17	2863-2865	NO	abstract	giv	coref	21-4[164_0]
18-18	2866-2871	after	_	_	_	_
18-19	2872-2873	a	abstract[147]	new[147]	_	_
18-20	2874-2882	moderate	abstract[147]	new[147]	_	_
18-21	2883-2895	photodynamic	abstract[147]	new[147]	_	_
18-22	2896-2905	challenge	abstract[147]	new[147]	_	_
18-23	2906-2916	sensitized	abstract[147]	new[147]	_	_
18-24	2917-2919	by	abstract[147]	new[147]	_	_
18-25	2920-2931	ALA-induced	abstract[147]|abstract[148]	new[147]|giv[148]	coref	22-13[0_148]
18-26	2932-2936	PpIX	abstract[147]|abstract[148]	new[147]|giv[148]	_	_
18-27	2937-2938	.	_	_	_	_

#Text=The iNOS/NO induction in PDT-surviving ( still attached ) cells was relatively rapid after irradiation ( 2 – 3 h ) and prolonged ( at least 24 h ) .
19-1	2939-2942	The	event[150]	new[150]	_	_
19-2	2943-2950	iNOS/NO	abstract|event[150]	new|new[150]	_	_
19-3	2951-2960	induction	event[150]	new[150]	_	_
19-4	2961-2963	in	event[150]	new[150]	_	_
19-5	2964-2977	PDT-surviving	event[150]|plant[151]	new[150]|giv[151]	coref	20-3[155_151]
19-6	2978-2979	(	event[150]|plant[151]	new[150]|giv[151]	_	_
19-7	2980-2985	still	event[150]|plant[151]	new[150]|giv[151]	_	_
19-8	2986-2994	attached	event[150]|plant[151]	new[150]|giv[151]	_	_
19-9	2995-2996	)	event[150]|plant[151]	new[150]|giv[151]	_	_
19-10	2997-3002	cells	event[150]|plant[151]	new[150]|giv[151]	_	_
19-11	3003-3006	was	_	_	_	_
19-12	3007-3017	relatively	_	_	_	_
19-13	3018-3023	rapid	_	_	_	_
19-14	3024-3029	after	_	_	_	_
19-15	3030-3041	irradiation	event	new	_	_
19-16	3042-3043	(	_	_	_	_
19-17	3044-3045	2	abstract[153]	new[153]	_	_
19-18	3046-3047	–	abstract[153]	new[153]	_	_
19-19	3048-3049	3	abstract[153]	new[153]	_	_
19-20	3050-3051	h	abstract[153]	new[153]	_	_
19-21	3052-3053	)	_	_	_	_
19-22	3054-3057	and	_	_	_	_
19-23	3058-3067	prolonged	_	_	_	_
19-24	3068-3069	(	_	_	_	_
19-25	3070-3072	at	time[154]	new[154]	coref	23-16[184_154]
19-26	3073-3078	least	time[154]	new[154]	_	_
19-27	3079-3081	24	time[154]	new[154]	_	_
19-28	3082-3083	h	time[154]	new[154]	_	_
19-29	3084-3085	)	_	_	_	_
19-30	3086-3087	.	_	_	_	_

#Text=Importantly , these cells exhibited a more aggressive growth , migratory , and invasive phenotype than non-photostressed controls , and this was suppressed by inhibition of iNOS or by NO scavenging .
20-1	3088-3099	Importantly	_	_	_	_
20-2	3100-3101	,	_	_	_	_
20-3	3102-3107	these	plant[155]	giv[155]	coref	21-8[165_155]
20-4	3108-3113	cells	plant[155]	giv[155]	_	_
20-5	3114-3123	exhibited	_	_	_	_
20-6	3124-3125	a	abstract[157]	new[157]	ana	20-21[0_157]
20-7	3126-3130	more	abstract[156]|abstract[157]	new[156]|new[157]	_	_
20-8	3131-3141	aggressive	abstract[156]|abstract[157]	new[156]|new[157]	_	_
20-9	3142-3148	growth	abstract[156]|abstract[157]	new[156]|new[157]	_	_
20-10	3149-3150	,	abstract[157]	new[157]	_	_
20-11	3151-3160	migratory	abstract[157]	new[157]	_	_
20-12	3161-3162	,	abstract[157]	new[157]	_	_
20-13	3163-3166	and	abstract[157]	new[157]	_	_
20-14	3167-3175	invasive	abstract[157]	new[157]	_	_
20-15	3176-3185	phenotype	abstract[157]	new[157]	_	_
20-16	3186-3190	than	abstract[157]	new[157]	_	_
20-17	3191-3208	non-photostressed	abstract[157]|event[158]	new[157]|new[158]	_	_
20-18	3209-3217	controls	abstract[157]|event[158]	new[157]|new[158]	_	_
20-19	3218-3219	,	_	_	_	_
20-20	3220-3223	and	_	_	_	_
20-21	3224-3228	this	abstract	giv	_	_
20-22	3229-3232	was	_	_	_	_
20-23	3233-3243	suppressed	_	_	_	_
20-24	3244-3246	by	_	_	_	_
20-25	3247-3257	inhibition	event[160]	new[160]	_	_
20-26	3258-3260	of	event[160]	new[160]	_	_
20-27	3261-3265	iNOS	event[160]|abstract	new[160]|giv	_	_
20-28	3266-3268	or	_	_	_	_
20-29	3269-3271	by	_	_	_	_
20-30	3272-3274	NO	event[162]	new[162]	_	_
20-31	3275-3285	scavenging	event[162]	new[162]	_	_
20-32	3286-3287	.	_	_	_	_

#Text=We postulated that induced diffusible NO from PDT-targeted cells might elicit a pro-growth/migratory response in non- or minimally-targeted bystander cells .
21-1	3288-3290	We	person	giv	ana	23-8
21-2	3291-3301	postulated	_	_	_	_
21-3	3302-3306	that	_	_	_	_
21-4	3307-3314	induced	abstract[164]	giv[164]	_	_
21-5	3315-3325	diffusible	abstract[164]	giv[164]	_	_
21-6	3326-3328	NO	abstract[164]	giv[164]	_	_
21-7	3329-3333	from	abstract[164]	giv[164]	_	_
21-8	3334-3346	PDT-targeted	abstract[164]|plant[165]	giv[164]|giv[165]	coref	21-16[168_165]
21-9	3347-3352	cells	abstract[164]|plant[165]	giv[164]|giv[165]	_	_
21-10	3353-3358	might	_	_	_	_
21-11	3359-3365	elicit	_	_	_	_
21-12	3366-3367	a	event[166]	giv[166]	_	_
21-13	3368-3388	pro-growth/migratory	event[166]	giv[166]	_	_
21-14	3389-3397	response	event[166]	giv[166]	_	_
21-15	3398-3400	in	event[166]	giv[166]	_	_
21-16	3401-3405	non-	event[166]|plant[168]	giv[166]|giv[168]	coref	23-2[180_168]
21-17	3406-3408	or	event[166]|plant[168]	giv[166]|giv[168]	_	_
21-18	3409-3427	minimally-targeted	event[166]|plant[168]	giv[166]|giv[168]	_	_
21-19	3428-3437	bystander	event[166]|person|plant[168]	giv[166]|new|giv[168]	coref	23-13
21-20	3438-3443	cells	event[166]|plant[168]	giv[166]|giv[168]	_	_
21-21	3444-3445	.	_	_	_	_

#Text=In an actual tumor , such targeting diversity might result from uneven PS distribution due to irregularities in the tumor microvasculature .
22-1	3446-3448	In	_	_	_	_
22-2	3449-3451	an	object[169]	giv[169]	coref	22-20[0_169]
22-3	3452-3458	actual	object[169]	giv[169]	_	_
22-4	3459-3464	tumor	object[169]	giv[169]	_	_
22-5	3465-3466	,	_	_	_	_
22-6	3467-3471	such	abstract[171]	new[171]	_	_
22-7	3472-3481	targeting	abstract|abstract[171]	new|new[171]	_	_
22-8	3482-3491	diversity	abstract[171]	new[171]	_	_
22-9	3492-3497	might	_	_	_	_
22-10	3498-3504	result	_	_	_	_
22-11	3505-3509	from	_	_	_	_
22-12	3510-3516	uneven	abstract[173]	new[173]	_	_
22-13	3517-3519	PS	abstract|abstract[173]	giv|new[173]	_	_
22-14	3520-3532	distribution	abstract[173]	new[173]	_	_
22-15	3533-3536	due	_	_	_	_
22-16	3537-3539	to	_	_	_	_
22-17	3540-3554	irregularities	abstract[174]	new[174]	_	_
22-18	3555-3557	in	abstract[174]	new[174]	_	_
22-19	3558-3561	the	abstract[174]|substance[176]	new[174]|new[176]	_	_
22-20	3562-3567	tumor	abstract[174]|object|substance[176]	new[174]|giv|new[176]	_	_
22-21	3568-3584	microvasculature	abstract[174]|substance[176]	new[174]|new[176]	_	_
22-22	3585-3586	.	_	_	_	_

#Text=Using photosensitized prostate cancer PC3 cells , we recently observed NO-mediated hyper-aggressive bystander effects for the first time in the context of PDT .
23-1	3587-3592	Using	_	_	_	_
23-2	3593-3608	photosensitized	plant[180]	giv[180]	coref	24-34[203_180]
23-3	3609-3617	prostate	place|abstract[178]|plant[180]	new|giv[178]|giv[180]	coref|coref	24-13[0_178]|24-26
23-4	3618-3624	cancer	abstract[178]|plant[180]	giv[178]|giv[180]	_	_
23-5	3625-3628	PC3	substance|plant[180]	new|giv[180]	coref	24-26[200_0]
23-6	3629-3634	cells	plant[180]	giv[180]	_	_
23-7	3635-3636	,	_	_	_	_
23-8	3637-3639	we	person	giv	ana	24-6
23-9	3640-3648	recently	_	_	_	_
23-10	3649-3657	observed	_	_	_	_
23-11	3658-3669	NO-mediated	abstract[183]	giv[183]	_	_
23-12	3670-3686	hyper-aggressive	abstract[183]	giv[183]	_	_
23-13	3687-3696	bystander	person|abstract[183]	giv|giv[183]	coref	24-34
23-14	3697-3704	effects	abstract[183]	giv[183]	_	_
23-15	3705-3708	for	_	_	_	_
23-16	3709-3712	the	time[184]	giv[184]	_	_
23-17	3713-3718	first	time[184]	giv[184]	_	_
23-18	3719-3723	time	time[184]	giv[184]	_	_
23-19	3724-3726	in	_	_	_	_
23-20	3727-3730	the	abstract[185]	new[185]	_	_
23-21	3731-3738	context	abstract[185]	new[185]	_	_
23-22	3739-3741	of	abstract[185]	new[185]	_	_
23-23	3742-3745	PDT	abstract[185]|abstract	new[185]|giv	_	_
23-24	3746-3747	.	_	_	_	_

#Text=In the present study , we compared the ability of four PDT-treated cancer lines ( melanoma BLM , glioblastoma U87 , breast MDA-MB-231 , and prostate PC3 ) to stimulate NO-dependent aggressiveness in bystander cells of the same type .
24-1	3748-3750	In	_	_	_	_
24-2	3751-3754	the	abstract[187]	new[187]	_	_
24-3	3755-3762	present	abstract[187]	new[187]	_	_
24-4	3763-3768	study	abstract[187]	new[187]	_	_
24-5	3769-3770	,	_	_	_	_
24-6	3771-3773	we	person	giv	_	_
24-7	3774-3782	compared	_	_	_	_
24-8	3783-3786	the	abstract[189]	new[189]	_	_
24-9	3787-3794	ability	abstract[189]	new[189]	_	_
24-10	3795-3797	of	abstract[189]	new[189]	_	_
24-11	3798-3802	four	abstract[189]|object[191]	new[189]|giv[191]	appos	24-16[194_191]
24-12	3803-3814	PDT-treated	abstract[189]|object[191]	new[189]|giv[191]	_	_
24-13	3815-3821	cancer	abstract[189]|abstract|object[191]	new[189]|giv|giv[191]	_	_
24-14	3822-3827	lines	abstract[189]|object[191]	new[189]|giv[191]	_	_
24-15	3828-3829	(	_	_	_	_
24-16	3830-3838	melanoma	animal|abstract[193]|object[194]	new|new[193]|giv[194]	_	_
24-17	3839-3842	BLM	abstract[193]|object[194]	new[193]|giv[194]	_	_
24-18	3843-3844	,	object[194]	giv[194]	_	_
24-19	3845-3857	glioblastoma	object[194]|abstract|abstract[196]	giv[194]|new|new[196]	_	_
24-20	3858-3861	U87	object[194]|abstract[196]	giv[194]|new[196]	_	_
24-21	3862-3863	,	object[194]	giv[194]	_	_
24-22	3864-3870	breast	object[194]|place|abstract[198]	giv[194]|new|new[198]	_	_
24-23	3871-3881	MDA-MB-231	object[194]|abstract[198]	giv[194]|new[198]	_	_
24-24	3882-3883	,	object[194]	giv[194]	_	_
24-25	3884-3887	and	object[194]	giv[194]	_	_
24-26	3888-3896	prostate	object[194]|place|substance[200]	giv[194]|giv|giv[200]	_	_
24-27	3897-3900	PC3	object[194]|substance[200]	giv[194]|giv[200]	_	_
24-28	3901-3902	)	_	_	_	_
24-29	3903-3905	to	_	_	_	_
24-30	3906-3915	stimulate	_	_	_	_
24-31	3916-3928	NO-dependent	abstract[201]	new[201]	_	_
24-32	3929-3943	aggressiveness	abstract[201]	new[201]	_	_
24-33	3944-3946	in	abstract[201]	new[201]	_	_
24-34	3947-3956	bystander	abstract[201]|person|plant[203]	new[201]|giv|giv[203]	_	_
24-35	3957-3962	cells	abstract[201]|plant[203]	new[201]|giv[203]	_	_
24-36	3963-3965	of	abstract[201]|plant[203]	new[201]|giv[203]	_	_
24-37	3966-3969	the	abstract[201]|plant[203]|abstract[204]	new[201]|giv[203]|new[204]	_	_
24-38	3970-3974	same	abstract[201]|plant[203]|abstract[204]	new[201]|giv[203]|new[204]	_	_
24-39	3975-3979	type	abstract[201]|plant[203]|abstract[204]	new[201]|giv[203]|new[204]	_	_
24-40	3980-3981	.	_	_	_	_
